Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 2'-fluoro‑2'-deoxyuridine 3′‑monophosphate is a synthetic nucleoside monophosphate analog of deoxyuridine in which the hydrogen at the ribose sugar's C‑position is replaced by fluorine. It belongs to the class of pyrimidine antimetabolites and is structurally related to floxuridine (FUDR), a prodrug of fluorouracil. The compound acts as an inhibitor of thymidylate synthase by mimicking natural nucleotide substrates and interfering with DNA synthesis. This mechanism underlies its potential as an experimental antimetabolite for research into cancer therapeutics and possibly antimicrobial activity[1][7][8]. **Mechanism of Action:** - Inhibits thymidylate synthase by acting as a fraudulent nucleotide substrate. - Interferes with DNA synthesis through inhibition of dTMP production. - May be incorporated into nucleic acids or act as a precursor for further phosphorylated metabolites that disrupt cell proliferation[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-fluoro-2'-deoxyuridine 3'-monophosphate.